Safety and efficacy of weekly somapacitan for growth hormone deficiency in children
Weekly somapacitan offers an effective, safe pediatric GHD treatment, with individualized dosing based on IGF-1 levels. Routine IGF-1 monitoring is advised to maximize benefits and minimize risks. Further studies on diverse populations are recommended to validate these findings in pediatric endocrinology.
Authors
- Aliaa Alamri
- Abdulmoein Eid Al-Agha (ORCID: https://orcid.org/0000-0002-7168-6447)
- Shahd E Kafi
- Hasan Aljefri
- Abdullah A. Alghamdi (ORCID: https://orcid.org/0000-0002-7400-3154)
Institutions
- King Abdulaziz Hospital (SA)
Publication Details
- Journal
- Saudi Medical Journal
- Published
- 2025-03-01
- DOI
- https://doi.org/10.15537/smj.2025.46.3.20240937
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00